Mycovia Pharmaceuticals has a passion for developing breakthrough therapies in areas of unmet medical need. Oteseconazole (VT-1161), is a novel, oral therapy for Recurrent Vulvovaginal Candidiasis (RVVC) that is designed to have greater selectivity and improved efficacy. Please visit www.mycovia.com
Additional Info
The contact information provided may be used in the printed program, mobile app, and online exhibitor directory.
Yes